Details of the Drug

General Information of Drug (ID: DMW67MU)

Drug Name

Botulinum Toxin Type A

Synonyms

Botox; Botulinum toxin type A (JAN)

Indication

Disease Entry	ICD 11	Status	REF
Blepharospasm	9A05.Z	Approved	[1]
------------------------------------------------------------------------------------

Sequence

MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA
KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV
LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT
GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE
ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA
AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG
AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK
VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA
MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK
VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI
GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN
EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT
NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN
EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR
GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK
LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 230 - 260 minutes [2]

Cross-matching ID

DrugBank ID: DB00083
TTD ID: D0D1RM

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Synaptosomal-associated protein 25 (SNAP25)	TTYQWA0	SNP25_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Botulinum Toxin Type A (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Scopolamine.	Addictive disorder [6C50-6C5Z]	[4]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[4]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[4]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[4]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[4]
Promazine	DMZAL7W	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Promazine.	Appearance/behaviour symptom [MB23]	[4]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[4]
Imipramine	DM2NUH3	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Imipramine.	Depression [6A70-6A7Z]	[4]
Nortriptyline	DM4KDYJ	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Nortriptyline.	Depression [6A70-6A7Z]	[4]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Clomipramine.	Depression [6A70-6A7Z]	[4]
Amitriptyline	DMK7F9S	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Amitriptyline.	Depression [6A70-6A7Z]	[4]
Amoxapine	DMKITQE	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Amoxapine.	Depression [6A70-6A7Z]	[4]
Protriptyline	DMNHTZI	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Protriptyline.	Depression [6A70-6A7Z]	[4]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Doxepin.	Depression [6A70-6A7Z]	[4]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Maprotiline.	Depression [6A70-6A7Z]	[4]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Hyoscyamine.	Digestive system disease [DE2Z]	[4]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Mepenzolate.	Digestive system disease [DE2Z]	[4]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Meclizine.	Dizziness and giddiness [MB48]	[4]
Trihexyphenidyl	DMB19L8	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Trihexyphenidyl.	Dystonic disorder [8A02]	[4]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Solifenacin.	Functional bladder disorder [GC50]	[4]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Tolterodine.	Functional bladder disorder [GC50]	[4]
Darifenacin	DMWXLYZ	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Darifenacin.	Functional bladder disorder [GC50]	[4]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Propantheline.	Gastric ulcer [DA60]	[4]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[4]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Propiomazine.	Insomnia [7A00-7A0Z]	[4]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Clidinium.	Irritable bowel syndrome [DD91]	[4]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Dicyclomine.	Irritable bowel syndrome [DD91]	[4]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Phenindamine.	Nasopharyngitis [CA00]	[4]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Dimenhydrinate.	Nausea/vomiting [MD90]	[4]
Prochlorperazine	DM53SRA	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Prochlorperazine.	Nausea/vomiting [MD90]	[4]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Promethazine.	Nausea/vomiting [MD90]	[4]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Cyclizine.	Nausea/vomiting [MD90]	[4]
Thiethylperazine	DMU3IET	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Thiethylperazine.	Nausea/vomiting [MD90]	[4]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Flavoxate.	Pain [MG30-MG3Z]	[4]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Biperiden.	Parkinsonism [8A00]	[4]
Benztropine	DMGZOVN	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Benztropine.	Parkinsonism [8A00]	[4]
Procyclidine	DMHFJDT	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Procyclidine.	Parkinsonism [8A00]	[4]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Methylscopolamine.	Peptic ulcer [DA61]	[4]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Levomepromazine.	Psychotic disorder [6A20-6A25]	[4]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Fluphenazine.	Psychotic disorder [6A20-6A25]	[4]
Triflupromazine	DMKFQJP	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Triflupromazine.	Psychotic disorder [6A20-6A25]	[4]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Cyproheptadine.	Rheumatoid arthritis [FA20]	[4]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Mesoridazine.	Schizophrenia [6A20]	[4]
Thioridazine	DM35M8J	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Thioridazine.	Schizophrenia [6A20]	[4]
Loxapine	DM8AI9U	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Loxapine.	Schizophrenia [6A20]	[4]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Perphenazine.	Schizophrenia [6A20]	[4]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Molindone.	Schizophrenia [6A20]	[4]
Chlorpromazine	DMBGZI3	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Chlorpromazine.	Schizophrenia [6A20]	[4]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Thiothixene.	Schizophrenia [6A20]	[4]
Clozapine	DMFC71L	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Clozapine.	Schizophrenia [6A20]	[4]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Trifluoperazine.	Schizophrenia [6A20]	[4]
Olanzapine	DMPFN6Y	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Olanzapine.	Schizophrenia [6A20]	[4]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Pimozide.	Schizophrenia [6A20]	[4]
Trospium	DMX6RTG	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Trospium.	Tonus and reflex abnormality [MB47]	[4]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[4]
Triprolidine	DM7SWIA	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[4]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[4]
Clemastine	DMBZWQL	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Clemastine.	Vasomotor/allergic rhinitis [CA08]	[4]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[4]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[4]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[4]
Dexbrompheniramine	DMKVWGE	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Dexbrompheniramine.	Vasomotor/allergic rhinitis [CA08]	[4]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[4]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[4]
Disopyramide	DM5SYZP	Moderate	Additive anticholinergic effects by the combination of Botulinum Toxin Type A and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[4]
-----------


⏷ Show the Full List of 65 DDI Information of This Drug

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	FDA Approved Products: Botox (onabotulinumtoxinA) for injection
3	Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct duration... J Biol Chem. 2003 Jan 10;278(2):1363-71.
4	Product Information. Botox (onabotulinumtoxin A). Allergan Inc, Irvine, CA.